Hakan Goker (Ph.D.) is Vice President and responsible for healthcare investments at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan has been investing for the past 15 years as a partner at Aescap Venture and prior to that as part of Atlas Venture life sciences team, joining M Ventures in 2013.
Since 2006, Hakan has been instrumental in the creation, financing, and corporate strategy of multiple biotechnology companies globally including Artios, Asceneuron, Ribometrix, Storm, Bicycle, and F-star. Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital.
He gained his BSc Honours, from University College London. Hakan represents M Ventures on the boards of Artios Pharma, Forendo, Ribometrix Inc., Storm Therapeutics, iOnctura, and others, and was the board member at Progyny Inc. prior to company’s public listing
